Sanofi Healthcare India Pvt. Ltd. has announced a major breakthrough in the treatment of moderate-to-severe atopic dermatitis with the authorization of Dupixent® (dupilumab). This innovative biologic medicine is a game-changer for adults with atopic dermatitis, offering a viable treatment alternative to those who have not found relief with traditional topical prescription therapies.
Dupixent® stands apart in the treatment landscape as it targets the type 2 inflammation at the root of atopic dermatitis instead of suppressing the immune system broadly. This has revolutionized the treatment approach for patients globally.
Atopic dermatitis, a variant of eczema, is a chronic type 2 inflammatory disease marked by skin rashes, intense itching, and skin dryness. These symptoms, often persistent and debilitating, significantly impair patients’ quality of life, leading to disrupted sleep, anxiety, depression, and even social stigma.
Already a proven therapy in over 60 countries including the U.S., the European Union, and Japan, Dupixent® now seeks to bring relief to the Indian demographic grappling with this tough-to-treat skin condition. A product of a global collaboration between Sanofi and Regeneron, Dupixent® has already improved the lives of over 600,000 patients worldwide, demonstrating that a better quality of life for adults with moderate-to-severe atopic dermatitis is achievable.